28464602|t|Attenuation of High Glucose - Induced Rat Cardiomyocyte Apoptosis by Exendin-4 via Intervention of HO-1 / Nrf-2 and the PI3K/AKT Signaling Pathway
28464602|a|Exendin-4, a glucagon-like peptide-1 receptor agonist, demonstrated cytoprotective actions beyond glycemic control in recent studies. The aims of the present study were to investigate the effects of exendin-4 on high glucose (HG)- induced cardiomyocyte apoptosis and the possible mechanisms. Rat cardiomyocytes were divided into 3 groups: normal glucose group (NG group), HG group and HG + exendin-4 group (HG + Ex Group). Cardiomyocyte apoptosis was evaluated by double-staining with annexin V-fluorescein isothiocyanate (FITC)/ propidium iodide (PI) and flow cytometry. Intracellular reactive oxygen species (ROS) production was detected by 2’,7’-dichlorodihydrofluorescein diacetate (DCHF-DA) incubation and fluorescence microscopy. LY294002 (LY), a phosphoinositide 3-kinase (PI3K) pathway inhibitor, was added to the medium of the HG + Ex + LY Group for further western blot analysis. The proteins analyzed involved oxidative stress - associated proteins, heme oxygenase-1 (HO-1) and nuclear factor E2-related factor 2 (Nrf-2), and apoptosis - associated proteins, caspase-3, Bax/B-cell lymphoma 2 (Bcl-2) and p-AKT / AKT. HG treatment induced cardiomyocyte apoptosis (P = 0.00) and clearly upregulated ROS production (P = 0.00); exendin-4 co-incubation also ameliorated cardiomyocyte apoptosis (P = 0.004) and decreased ROS (P = 0.00) level significantly. HO-1 and Nrf-2 protein expression levels decreased significantly in the HG group (P < 0.05), but the levels were elevated by exendin-4 intervention (P < 0.05). Furthermore, exendin-4 attenuated HG - induced higher protein expression, including cleaved caspase-3 and Bax, increased the expression of Bcl-2 protein (P < 0.05). However, these impacts of exendin-4 were counteracted significantly by co-incubation with LY294002. In addition, exendin-4 ameliorated HG - induced p-AKT / AKT lower expression, and this impact was also suppressed by LY294002. Exendin-4 ameliorates HG - induced cardiomyocyte apoptosis, and the mechanisms may involve anti-oxidative stress via the HO-1 / Nrf-2 system, as well as intervention of the PI3K/AKT signaling pathway.
28464602	0	11	Attenuation	T052	C0599946
28464602	15	27	High Glucose	T109,T121,T123	C0017725
28464602	30	37	Induced	T169	C0205263
28464602	38	41	Rat	T015	C0034693
28464602	42	55	Cardiomyocyte	T025	C0225828
28464602	56	65	Apoptosis	T043	C0162638
28464602	69	78	Exendin-4	T116,T121	C0167117
28464602	83	95	Intervention	T061	C0184661
28464602	99	103	HO-1	T116,T126	C0538674
28464602	106	111	Nrf-2	T116,T123	C0289507
28464602	120	146	PI3K/AKT Signaling Pathway	T169	C2984369
28464602	147	156	Exendin-4	T116,T121	C0167117
28464602	160	200	glucagon-like peptide-1 receptor agonist	T121	C2917359
28464602	215	237	cytoprotective actions	T039	C0524828
28464602	245	261	glycemic control	T033	C0522082
28464602	285	289	aims	T078	C1947946
28464602	305	310	study	T062	C2603343
28464602	319	330	investigate	T169	C1292732
28464602	335	345	effects of	T080	C1704420
28464602	346	355	exendin-4	T116,T121	C0167117
28464602	359	371	high glucose	T109,T121,T123	C0017725
28464602	373	375	HG	T109,T121,T123	C0017725
28464602	378	385	induced	T169	C0205263
28464602	386	399	cardiomyocyte	T025	C0225828
28464602	400	409	apoptosis	T043	C0162638
28464602	427	437	mechanisms	T169	C0441712
28464602	439	442	Rat	T015	C0034693
28464602	443	457	cardiomyocytes	T025	C0225828
28464602	478	484	groups	UnknownType	C0681860
28464602	486	500	normal glucose	T109,T121,T123	C0017725
28464602	501	506	group	UnknownType	C0681860
28464602	508	510	NG	T109,T121,T123	C0017725
28464602	511	516	group	UnknownType	C0681860
28464602	519	521	HG	T109,T121,T123	C0017725
28464602	522	527	group	UnknownType	C0681860
28464602	532	534	HG	T109,T121,T123	C0017725
28464602	537	546	exendin-4	T116,T121	C0167117
28464602	547	552	group	UnknownType	C0681860
28464602	554	556	HG	T109,T121,T123	C0017725
28464602	559	561	Ex	T116,T121	C0167117
28464602	562	567	Group	UnknownType	C0681860
28464602	570	583	Cardiomyocyte	T025	C0225828
28464602	584	593	apoptosis	T043	C0162638
28464602	611	626	double-staining	T059	C0022885
28464602	632	668	annexin V-fluorescein isothiocyanate	T109,T130	C0085216
28464602	670	674	FITC	T109,T130	C0085216
28464602	677	693	propidium iodide	T109,T130	C0033470
28464602	695	697	PI	T109,T130	C0033470
28464602	703	717	flow cytometry	T059	C0016263
28464602	719	732	Intracellular	T082	C0178719
28464602	733	762	reactive oxygen species (ROS)	T123	C1537052
28464602	763	773	production	T169	C0542341
28464602	778	786	detected	T033	C0442726
28464602	790	832	2’,7’-dichlorodihydrofluorescein diacetate	T109,T130	C0670829
28464602	834	841	DCHF-DA	T109,T130	C0670829
28464602	843	853	incubation	T059	C1439852
28464602	858	881	fluorescence microscopy	T059	C0026022
28464602	883	891	LY294002	T109,T121	C0251991
28464602	893	895	LY	T109,T121	C0251991
28464602	900	925	phosphoinositide 3-kinase	T116,T126	C0044602
28464602	927	931	PI3K	T116,T126	C0044602
28464602	933	940	pathway	T044	C1704259
28464602	941	950	inhibitor	T080	C1999216
28464602	969	975	medium	T130	C0010454
28464602	983	985	HG	T109,T121,T123	C0017725
28464602	988	990	Ex	T116,T121	C0167117
28464602	993	995	LY	T109,T121	C0251991
28464602	996	1001	Group	UnknownType	C0681860
28464602	1014	1035	western blot analysis	T059	C0949466
28464602	1041	1049	proteins	T116,T123	C0033684
28464602	1050	1058	analyzed	T062	C0936012
28464602	1068	1084	oxidative stress	T049	C0242606
28464602	1087	1106	associated proteins	T116,T123	C0033684
28464602	1108	1124	heme oxygenase-1	T116,T126	C0538674
28464602	1126	1130	HO-1	T116,T126	C0538674
28464602	1136	1170	nuclear factor E2-related factor 2	T116,T123	C0289507
28464602	1172	1177	Nrf-2	T116,T123	C0289507
28464602	1184	1193	apoptosis	T043	C0162638
28464602	1196	1215	associated proteins	T116,T123	C0033684
28464602	1217	1226	caspase-3	T116,T126	C0291573
28464602	1228	1249	Bax/B-cell lymphoma 2	T116,T123	C0219474
28464602	1251	1256	Bcl-2	T116,T123	C0219474
28464602	1262	1267	p-AKT	T116,T126	C0164786
28464602	1270	1273	AKT	T116,T126	C0164786
28464602	1275	1277	HG	T109,T121,T123	C0017725
28464602	1278	1287	treatment	T169	C1522326
28464602	1288	1295	induced	T169	C0205263
28464602	1296	1309	cardiomyocyte	T025	C0225828
28464602	1310	1319	apoptosis	T043	C0162638
28464602	1343	1354	upregulated	T044	C0041904
28464602	1355	1358	ROS	T123,T196	C0162772
28464602	1359	1369	production	T169	C0542341
28464602	1382	1391	exendin-4	T116,T121	C0167117
28464602	1392	1405	co-incubation	T059	C1439852
28464602	1423	1436	cardiomyocyte	T025	C0225828
28464602	1437	1446	apoptosis	T043	C0162638
28464602	1463	1472	decreased	T081	C0205216
28464602	1473	1476	ROS	T123,T196	C0162772
28464602	1488	1493	level	T080	C0441889
28464602	1494	1507	significantly	T078	C0750502
28464602	1509	1513	HO-1	T116,T126	C0538674
28464602	1518	1523	Nrf-2	T116,T123	C0289507
28464602	1524	1542	protein expression	T045	C1171362
28464602	1543	1549	levels	T080	C0441889
28464602	1550	1559	decreased	T081	C0205216
28464602	1560	1573	significantly	T078	C0750502
28464602	1581	1583	HG	T109,T121,T123	C0017725
28464602	1584	1589	group	UnknownType	C0681860
28464602	1610	1616	levels	T080	C0441889
28464602	1622	1630	elevated	T080	C3163633
28464602	1634	1643	exendin-4	T116,T121	C0167117
28464602	1644	1656	intervention	T061	C0184661
28464602	1682	1691	exendin-4	T116,T121	C0167117
28464602	1692	1702	attenuated	T052	C0599946
28464602	1703	1705	HG	T109,T121,T123	C0017725
28464602	1708	1715	induced	T169	C0205263
28464602	1723	1741	protein expression	T045	C1171362
28464602	1761	1770	caspase-3	T116,T126	C0291573
28464602	1775	1778	Bax	T116,T123	C0219474
28464602	1780	1789	increased	T081	C0205217
28464602	1794	1804	expression	T045	C1171362
28464602	1808	1821	Bcl-2 protein	T116	C4042483
28464602	1849	1856	impacts	T080	C4049986
28464602	1860	1869	exendin-4	T116,T121	C0167117
28464602	1888	1901	significantly	T078	C0750502
28464602	1905	1918	co-incubation	T059	C1439852
28464602	1924	1932	LY294002	T109,T121	C0251991
28464602	1947	1956	exendin-4	T116,T121	C0167117
28464602	1969	1971	HG	T109,T121,T123	C0017725
28464602	1974	1981	induced	T169	C0205263
28464602	1982	1987	p-AKT	T116,T126	C0164786
28464602	1990	1993	AKT	T116,T126	C0164786
28464602	1994	2010	lower expression	T045	C1171362
28464602	2021	2027	impact	T080	C4049986
28464602	2037	2047	suppressed	T169	C1260953
28464602	2051	2059	LY294002	T109,T121	C0251991
28464602	2061	2070	Exendin-4	T116,T121	C0167117
28464602	2083	2085	HG	T109,T121,T123	C0017725
28464602	2088	2095	induced	T169	C0205263
28464602	2096	2109	cardiomyocyte	T025	C0225828
28464602	2110	2119	apoptosis	T043	C0162638
28464602	2129	2139	mechanisms	T169	C0441712
28464602	2152	2173	anti-oxidative stress	T044	C1148560
28464602	2182	2186	HO-1	T116,T126	C0538674
28464602	2189	2194	Nrf-2	T116,T123	C0289507
28464602	2214	2226	intervention	T061	C0184661
28464602	2234	2260	PI3K/AKT signaling pathway	T169	C2984369